Rapid COVID-19 Passive Therapy Response Platform

Projektinformationen

RapCo-19

ID Finanzhilfevereinbarung: 961845

DOI

10.3030/961845

Projekt abgeschlossen

EK-Unterschriftsdatum 28 Juli 2020

Startdatum 1 September 2020

Enddatum 31 Mai 2022

Finanziert unter

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Gesamtkosten

€ 4 500 000,00

EU-Beitrag

€ 2 500 000,00

Koordiniert durch

REMEDY BIOLOGICS LIMITED
Ireland

CORDIS bietet Links zu öffentlichen Ergebnissen und Veröffentlichungen von HORIZONT-Projekten.

Links zu Ergebnissen und Veröffentlichungen von RP7-Projekten sowie Links zu einigen Typen spezifischer Ergebnisse wie Datensätzen und Software werden dynamisch von OpenAIRE abgerufen.

Leistungen

Demonstrators, pilots, prototypes (3)

Proven pre-clinical safety and efficacy of the SARS-CoV-2 vaccine and antibody drug product

Preclinical studies demonstrating the safety and efficacy of passive therapy in rodent models Data will be shared with the EIC

Highly purified antibody therapy for preclinical studies

Characterised lead candidates will be expressed and antibody purified for the direct passive therapy in preclinical studies Sufficient purified antibodyprotein will be generated to ensure full preclinical studies can be performed

Antibody DNA sequence of lead candidate(s)

Recombinant antibody DNA and sequence information of lead candidates that can be provided to partners for cloningmanufacture in partner expression systems Providing recombinant DNA can provide rapid scaling through multiple partners

Open Research Data Pilot (1)

Deployment of SARS-Cov-2 antibody passive vaccine therapy

Remedy Biologics will partner with appropriate bigpharma and EU Government authorities to produce and deploy vaccines